Priya Patel, MD
Vascular Surgery · Anchorage, AKNPI 1124314315
Payments from drug & device makers
What this record shows
W. L. Gore & Associates, Inc. accounts for 72.2% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2023 at $2,673 and has fallen 86.0% since, to $375 in 2025.
Across 36 payments — averaging $160.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- W. L. Gore & Associates, Inc.$4K
- Silk Road Medical, Inc.$826
- Boston Scientific$260
- Inspiremd Ltd$129
- Shape Memory Medical Inc.$88
- Sanofi$81
- plus $227 from 5 others
What the payments were for
- Travel & lodging$3,46660%
- Food & beverage$2,32840%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| W. L. Gore & Associates, Inc. | 14 | $4,184 |
| Silk Road Medical, Inc. | 8 | $826 |
| Boston Scientific | 3 | $260 |
| Inspiremd Ltd | 1 | $129 |
| Shape Memory Medical Inc. | 1 | $88 |
| Sanofi | 1 | $81 |
| Medtronic | 1 | $76 |
| Lemaitre Vascular, Inc. | 3 | $63 |
| Cardiovascular Systems Inc. | 2 | $45 |
| Inari Medical, Inc. | 1 | $26 |
| Abbott | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis$1,684
- GORE TAG Thoracic Endoprosthesis$1,374
- ENROUTE Transcarotid Neuroprotection System$1,202
- GORE TAG Thoracic Branch Endoprosthesis$912
- ENROUTE Transcarotid Stent$602
- ENROUTE Enflate Transcarotid RX Balloon Dilatation Catheter$353
- CGuard Prime Carotid Stent System$129
How this compares
Too few vascular surgery providers in Alaskato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ClopidogrelClopidogrel Bisulfate | 54 | $748 |
Paid to pharmacies, not to this prescriber.
Other vascular surgery in Anchorage
- Jonathan McDonaghAnchorage$9K
- Jonathan BarnesAnchorage$8K
- Stanley WatkinsAnchorage$7K
- Galimat KhaidakovaAnchorage$5K
- Seth KraussAnchorage$1K
- April RodriguezAnchorage$997
- Milan BajmocziFairbanks$94K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.